Company news
Nuvation Bio Inc. (NYSE:NUVB) news
Every Nuvation Bio Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
August 20, 2026
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung ...
August 4, 2026
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
July 22, 2026
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad ...
July 20, 2026
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
July 6, 2026
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell L...
June 29, 2026
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
June 25, 2026
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer a...
May 27, 2026
Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung ...
May 13, 2026
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response...
May 6, 2026
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
May 4, 2026
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Gu...
April 27, 2026
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presen...
April 21, 2026
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
April 20, 2026
Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
April 1, 2026
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Sma...
March 26, 2026
Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Sm...
March 17, 2026
Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 2, 2026
Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026
February 17, 2026
Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma
February 9, 2026
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. ...
January 12, 2026
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China ...
January 12, 2026
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List
December 6, 2025
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in N...
December 3, 2025
Nuvation Bio to Participate in Upcoming Investor Conferences
November 26, 2025
Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
November 3, 2025
Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma
October 23, 2025
Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025
October 20, 2025
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Earl...
September 30, 2025
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive...
September 19, 2025
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung C...
September 7, 2025
Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update
August 7, 2025
Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual...
August 5, 2025
Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
July 24, 2025
Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guid...
June 24, 2025
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Po...
June 11, 2025
Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at A...
May 21, 2025
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025
May 13, 2025
Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025
Nuvation Bio to Present at The Citizens Life Sciences Conference
May 1, 2025
Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025
April 22, 2025
Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference
April 2, 2025
Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025
March 25, 2025
Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the ...
March 25, 2025
Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 6, 2025
Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners
March 3, 2025
Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025